XOLAIR (also known as Omalizumab)
Mechanism:
Xolair is an antibody that binds to human immunoglobulin E (IgE) and prevents the activation of cells that would otherwise mediate allergic reactions.
Indications:
Adults and adolescents (age >= 12) with moderate to severe asthma with positive skin test for perennial allergens and whose symptoms are not adequately controlled with inhaled corticosteroids.
Cautions:
Xolair should not be used for acute asthma exacerbations.
Administration:
Xolair is typically administered as a subcutaneous injection by a healthcare administrator. Patient should be monitored afterwards for possible allergic reaction.